7月2日，药明生物盘中上涨3.47%，报35.92港元/股，成交额5.09亿港元。
消息面上，公司近期维持高频回购节奏，6月30日斥资约9982.5万港元回购289万股，自5月26日以来累计回购逾3710.8万股，总代价约11.72亿港元，彰显管理层对公司价值的信心。此外，公司近日宣布其无锡生产基地三家工厂以"零发现项"通过巴西ANVISA GMP认证，进一步验证全球商业化生产能力。板块方面，生命科学工具和服务行业个股走强，药明合联涨3.68%、金斯瑞生物科技涨4.33%，板块共振效应显著。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.